Immune checkpoint inhibitors (ICIs) are approved for several types of cancer but can cause ICI-associated myocarditis, a rare but life-threatening condition. The authors, led by Lorenz Lehmann from the DZHK partner site in Heidelberg, were able to show that troponin-T is associated with major adverse cardiomyotoxic events like heart failure, ventricular arrhythmia, atrioventricular or sinus block requiring a pacemaker, respiratory failure requiring mechanical ventilation and sudden cardiac death, and is sensitive for diagnosis and monitoring in patients with ICI-associated myocarditis.
Link zur Publikation:
Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis (Lehmann et al., 2023)
